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Abstract
The crucial position of IgE within the pathogenesis of allergic diseases made it a key tar-
get for therapy. The inhibition of the allergic inflammatory cascade by anti-immunoglob-
ulin E (IgE) therapy is a new and promising concept in the treatment of these diseases. 
Currently available anti-IgE agent omalizumab has been started to be used in past 3 
years in the cases of chronic spontaneous urticaria (CSU) and chronic inducible urticaria 
(CINDU), resistant to the first-, second-, and some third-line treatments. The use of omal-
izumab as an effective and safe biological therapy for inadequately controlled severe, 
persistent patients with CSU and CINDU provided a valuable new treatment option for 
these patients. However, the data about possible mechanisms of anti-IgE therapy in these 
patients, treatment strategies and dose regimens of anti-IgE therapy are different, and 
special patient groups and possible side effects are still insufficient. Also, studies about 
possible future anti-IgE treatment options are ongoing in CSU.
Keywords: chronic urticaria, anti-IgE therapy, omalizumab, management, new anti-IgE 
agents
1. Introduction
Chronic spontaneous urticaria (CSU) is defined as the spontaneous occurrence of itchy 
wheals, angioedema, or both for more than 6 weeks [1, 2]. More than 5 million people only 
in Europe suffer from CSU, especially its negative effects are on quality of life and sleep, 
school and work performance and daily life activities, and social relationships [3]. Recently, 
inside the EAACI/GA(2) LEN/EDF/WAO Guideline, it has been endorsed that nonsedating 
H1 antihistamines ought to be used for the first-line treatment of CSU and doses of H1 anti-
histamines can be increased by four-fold as the second-line treatment till symptoms can be 
kept under control completely [1, 4]. When these increased doses of H1 antihistamines fail, 
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one of the recommended therapies as the third-line treatment is omalizumab. It is the only 
available agent of anti-immunoglobulin E (IgE) at the current time [3, 4].
2. Role of IgE in CSU
IgE has an important role in the pathogenesis of many allergic disorders including asthma, 
allergic rhinitis, latex allergy, hyper-IgE syndrome, chronic rhinosinusitis, atopic dermatitis, 
food allergy, drug allergy, and CSU. However, the role of IgE levels has different mechanisms 
in pathogenesis and diagnosis of the leading allergic disorders. In support of this, IgE levels 
are not correlated with CSU severity [5].
Measurements of total IgE levels during anti-IgE therapy with conventional methods show 
increases by nearly 3- to 11-fold [6]. The increase in monthly IgE levels is explained by the 
fact that total IgE measured during therapy is made up of free IgE and IgE binds free IgE and 
forms a complex and that, daily IgE production continues [3]. This is explained in the litera-
ture that commercial kits used to determine IgE levels measure both free IgE and IgE-anti-IgE 
complex together [3, 7]. Therefore, it is recommended that total IgE should not be used for 
measurement of free IgE during omalizumab treatment [8].
It is known that immunocomplexes do not cause tissue damage or complement fixation. In 
addition, it is proposed that accumulation of immunocomplexes in the extravascular space 
(mucosal epithelial lining) and the inability of anti-IgE forming a complex with IgE to go back 
to capillary space creates a local space, protective against allergens [7].
The role of IgE measurements in planning treatment for chronic urticaria and adjustment of 
the dose of omalizumab is not clear yet [9]. A recent study has shown that basal IgE levels do 
not play a role in responses to treatment [3].
Serum total IgE levels are regulated by several factors in the absence of anti-IgE therapy. It 
is known that the baseline IgE can predict the clearance and rate of production of IgE [10], 
and baseline IgE levels have a greater dependence on IgE production than IgE clearance [11]. 
Thus, in patients with high IgE levels and high IgE production, separately omalizumab, rel-
evant IgE levels will come back after omalizumab loses its action as compared to patients with 
low IgE production and low IgE levels [6, 12]. Also, it was shown that, during the therapy, 
decrease in the serum concentration of free IgE is negatively correlated to the baseline IgE [6].
On the other hand, Lowe postulated that longer administration of omalizumab (1 year) 
decrease 56% of the IgE production [13]. Further studies with longer omalizumab administra-
tion may be highlighted in this topic.
The clearance of IgE is dependent on serum levels itself [10]. The half-life of serum free IgE is 
short (1 day) and changes in half-life of IgE are probably not very common and more likely an 
insignificant effect on regulation of IgE levels [14].
In a study, a different anti-IgE antibody (CGP 51901) was assessed in patients with another 
allergic disease rather than CSU. The half-life of the drug was negatively correlated to the free 
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baseline IgE levels. Also, the time for free IgE to return to baseline after anti-IgE treatment was 
negatively correlated with baseline IgE levels [15]. This issue may be summarized as higher 
IgE levels predict shorter half-life of anti-IgE antibody. However, the overall results from the 
studies are difficult to interpret in terms of their relevance because the administration of anti-
IgE was different, the observation period was different, and many other aspects of the subjects 
and the protocols were different. Also, Casale showed that serum concentration of free IgE is 
correlated to administrated doses of omalizumab. It was claimed that high doses administra-
tion of omalizumab, decreases the free IgE to the most stable levels [6].
3. Omalizumab therapy in CSU
It has been known since 2005 that omalizumab, a humanized immunoglobulin G1 (IgG1) mono-
clonal antibody which binds IgE, is well tolerated by patients with severe atopic asthma [16]. 
In 2014, as a first anti-IgE agent, omalizumab’s marketing authorization for CSU was approved 
first by European Medicines Agency and then by Food and Drug Administration [17].
Before 2014, there were few case reports on effects of omalizumab used; although not indi-
cated in patients with chronic urticaria, few studies on patients' experiences with omali-
zumab and omalizumab phase studies in larger groups of patients; however, there is still a 
limited number of studies on the use of omalizumab for the treatment of CSU in a real life 
context [4].
The characterization of the response to omalizumab treatment has been previously reported 
both in the controlled trials and in the case series [3, 4, 18]. But it is still unclear about the 
long-term management of anti-IgE therapy and possible side effects for the clinician. And, 
it is also unclear that when will patients show relapse after discontinuation of omalizumab 
treatment. Omalizumab discontinuation must be taken into consideration every 3–6 months 
[3, 19]. Patients who have relapsed after discontinuation of omalizumab, the reinitiation of 
omalizumab therapy is primarily based on modifications in medical factors and doctor's dis-
cretion [20]. Metz et al. have reported that, in the case of possible retreatment, resistance to 
omalizumab does not develop readily in most patients with CSU [20, 21].
It is not often found that an external trigger or any factors that can initiate the symptoms of 
CSU patients. Most patients with CSU have an autoimmune cause; therefore, autoimmunity 
can be considered firstly [22]. Some patients produce IgE autoantibodies (against thyroperoxi-
dase or double-stranded DNA) and IgG autoantibodies (against FcεRI and/or IgE), which lead 
to activate mast cells and basophils. Current reports have demonstrated that IgE, by means 
of binding to FcεRI on mast cells without FcεRI cross-linking, can boost the proliferation and 
survival of mast cells [23, 24]. Also, IgE and FcεRI engagement can also lower the release of 
mast cells and cause high sensitivity to various stimuli through both FcεRI and other recep-
tors. Eventually, in a case of stimuli, this process can give rise to degranulation of mast cells 
[23]. It is known that anti-IgE therapy shows its effect on urticaria through lowering unfas-
tened IgE levels and mast and basophil cell activations. It also downregulates an IgE receptor 
FceR1 in the mast, basophil, and dendritic cells [23].
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Finally, there are three different mechanisms of omalizumab in patients with CSU [22, 23];
i. Omalizumab sequesters monomeric IgE to lessen its priming effect on mast cells;
ii. In CSU patients with IgG autoantibodies in opposition to IgE or FcεRI, the depletion of 
mast cell IgE with the aid of omalizumab and the following downregulation of FcεRI on 
mast cells and basophils might lead to their reduced state of hyperexcitability;
iii. In those sufferers with IgE autoantibodies against autoallergens, the inhibition of IgE 
binding to FcεRI via omalizumab and the downregulation of FcεRI would represent a 
significant mechanism of omalizumab.
However, it is quite difficult to explain the mode of action of omalizumab based on elimina-
tion of IgE and the other three mechanisms. It is clear that further studies are needed to eluci-
date its mode of action in CSU.
3.1. The usage of omalizumab in chronic inducible urticaria (CINDU)
Chronic urticaria can also be spontaneous and/or inducible, though the triggers of induc-
ible urticaria [25]. CINDU emerges when triggered by physical stimuli including scratch, 
cold, heat, pressure, friction, exercise, sun exposure, water exposure, and exercise [19]. The 
term CINDU includes cold urticaria, delayed pressure urticaria, heat urticaria, solar urticaria, 
symptomatic dermographism, vibratory angioedema, aquagenic urticaria, cholinergic urti-
caria, and contact urticaria [19, 25].
The suggested dosing and indications of therapy are not different from that used for CSU 
in the patients with CINDU. It is either 150 or 300 mg/4 weeks given subcutaneously [3]. 
Even though, there are many large studies currently underway for CINDU [25], there are 
individual cases and smaller studies assessing the efficacy of omalizumab in various types 
of CINDU, while the number of overall cases is low. The results of these studies have shown 
that efficacy of omalizumab treatment is similar in CSU and CINDU patients [3, 9, 20, 21]. All 
recent studies and case reports have shown notable and optimistic outcome results in patients 
with CINDU [9].
3.2. The selection of patients and indications of omalizumab therapy
CSU patients who are planning to use omalizumab should meet the following conditions 
[1, 3, 19]:
1. Patients who are older than 12 years of age.
2. Patients who are underneath expert care (dermatologists and/or immunologists).
3. Cause of urticaria is not identifiable with the aid of further investigations and CBC, ANA, 
and urine analysis outcomes are not abnormal.
4. Patients are recognized with the aid of professionals as moderate to severe CSU that is not 
responsive to standard treatment.
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5. Disease period is longer than 3 months and the symptoms stay persistent notwithstanding 
using guideline primarily-based treatment.
3.3. Dose regimens and assessment of patients
The preliminary and continuation dosing is not similar to that used for asthma. Doses of 
omalizumab for asthma are adjusted based on weight and serum IgE levels [7]. The role of 
basal IgE levels in planning treatment for CSU and adjusting doses of omalizumab are not 
yet clear [26, 27]. Metz et al. have noted that basal IgE levels do not play a part in response to 
treatment [3]. Also in CSU patients, omalizumab is given 300 mg or 150 mg (sc) every 4 weeks 
and is not decided with the baseline serum IgE levels or patient's weight [1].
Two doses of omalizumab (150 mg or 300 mg/4 weeks) have been accepted by the USA Food 
and Drug Administration (FDA) for CSU refractory to H1 antihistamines. Uysal et al. intro-
duced an algorithm for defining dose, dose interval, and clinical response in CSU patients. 
Due to this set of rules, it is affordable to start omalizumab with a dose of 300 mg every 4 
weeks, and if the patient is good enough, taper to a lower dose (e.g., 150 mg every 4 weeks), 
or much less frequent injections (every 6 weeks) [27] (Figure 1). However, in a current meta-
analysis, wherein seven randomized, placebo-controlled studies determined substantial proof 
Figure 1. A practical individualization of omalizumab doses during the therapy.
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for the efficacy and safety of omalizumab in patients with CSU and to treat patients with CSU 
with 300 mg of omalizumab for 4 weeks [18].
3.4. Omalizumab therapy in special populations
Current guidelines of CSU consist of tips for special populations, especially children, the 
elderly, and pregnant or lactating women [1]. They suggest the similar management and 
treatment algorithms as adults but pay attention to factors such as age, dosage, and availabil-
ity of toddler-pleasant approaches [1].
3.5. Omalizumab therapy in children and elderly patients
Omalizumab is available as a third-line treatment for CSU in adolescent sufferers (≥12 years) 
with an insufficient response to antihistamine therapy, and is likewise approved for kids aged 
≥6 years with severe persistent allergic asthma [27]. Its efficacy and safety profile have been 
also shown in a case study in patients with CU aged <12 years [28]. There are no safety warn-
ings about omalizumab in the geriatric population [29].
3.6. Omalizumab therapy in pregnant and lactating women
There are limited posted records at the safety of omalizumab in pregnant women with CSU 
[30], despite the fact that available data about anti-IgE therapy are reassuring with other dis-
eases; however, the research in asthma patients showed no obvious increase or major anoma-
lies have been observed [31, 32]. The results have been now not distinct from those in women 
receiving placebo and other asthma therapies [33, 34].
The initiation of omalizumab in the course of pregnancy is not recommended, although if a 
woman turns into pregnant even as receiving omalizumab, it's far recommended that treat-
ment can persevere if the advantages are estimated to outweigh the possible harms [34]. 
Immunoglobulin G molecules, along with omalizumab, are known to pass the placenta. IgG 
is also excreted in human milk, so it would be predicted that a breastfeeding baby might be 
uncovered to omalizumab. Data in human beings are not available [34].
3.7. Adverse effects of omalizumab therapy
The most common unfavorable reaction derived from omalizumab is injection site reactions, 
including induration, itching, pain, and bruising. The package insert contains warnings con-
cerning about parasitic infections. While there are not any reports of fatal anaphylaxis due to 
omalizumab, a few cases have been serious and doubtlessly life-threatening [17].
Available information on the safety profile and tolerability of omalizumab therapy in patients 
with CSU has been mainly derived from the phase III trials in patients with CSU. ASTERIA 
I, ASTERIA II, and GLACIAL trials showed a good tolerability profile, which was similar to 
those with placebo and without any anaphylactic reactions [4, 5, 35].
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Limb et al. evaluated anaphylaxis and angioedema profiles of patients with asthma receiving 
omalizumab [36]. Polysorbate, a part of the drug used to increase its solubility, is very likely to 
be responsible for adverse reactions [36, 37]. In a report on two cases of atopic asthma on the 
long-term omalizumab therapy, the intradermal test showed that anaphylaxis is developed 
due to omalizumab [38]. Anaphylaxis due to omalizumab can be diagnosed; there should be 
at least two of the following symptoms: angioedema in the throat or in the tongue, broncho-
spasm, hypotension, syncope, and/or urticaria [39].
In a study performed by omalizumab joint task force (OJTF) in 2006, 0.09% of the asthmatic 
patients administered omalizumab had anaphylaxis. They reported that anaphylaxis due to 
omalizumab developed within 2 h of the administration, and after three injections of the drug 
in most of the patients (78%). Based on this finding, they recommended that patients should 
be monitored in the clinic for 2 h after the first three injections of omalizumab administration 
and for 30 min after the following injections [37].
Due to exacerbation of urticaria or angioedema normally appearing in the course of the CSU, 
the diagnosis of an adverse reaction can be overlooked. Therefore, possibilities of an adverse 
reaction, lack of a response to omalizumab, and exacerbations due to discontinuation of other 
medications should be kept in mind because a decision about whether the treatment is effec-
tive and should be continued has to be made.
In addition, since delayed adverse reactions due to omalizumab can appear, patients may 
think that these reactions are independent of the drug. They may not tell their doctors about 
them due to clinical benefits they receive from their treatment. Therefore, it is necessary that 
patients should be informed about possible adverse reactions before treatment and observed 
for a long time after treatment.
According to data we collected in the dermatology clinic in Education and Research Hospital, 
from 2014 to 2016, about 100 patients diagnosed as CSU were treated with omalizumab. One 
of these patients, after a long period of time without angioedema, had the first angioedema 
attack on the tongue within 30 min of omalizumab administration. The reaction appearing 
was regarded as an adverse effect or flare-up of urticaria. One patient had urticarial exacer-
bation and angioedema; hypotension, 30 min after the first omalizumab administration, and 
lack of any other symptoms were proposed to be a nonspecific adverse reaction. Exacerbation 
of urticaria and angioedema occurring after the second administration in the same patient 
were indicative of an adverse reaction. One patient had urticarial exacerbation; late-onset 
urticaria exacerbation after the first dose in was thought to be a delayed adverse reaction 
due to omalizumab or exacerbation of the disease because the previous cyclosporine therapy 
was discontinued [17]. Except those, two patients had localized urticarial plaque on the site 
of omalizumab application. One patient had a mild and one had a moderate headache, three 
patients had acneiform eruption and two patients had widespread foot pain and myalgia, 
which can be considered as the flu-like syndrome. One patient had dizziness. Omalizumab 
changed into discontinued within the patients experiencing urticarial exacerbation and/or 
angioedema, but the treatment became persevered within the patients located to have other 
adverse reactions and necessary precautions toward the side effects had been taken.
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4. Newly introduced anti-IgE therapies
As a third-line therapy in patients with CSU, omalizumab is an effective and safe biological 
therapy option for both antihistamine-resistant CSU patients and physicians dealing with 
CSU [40]. However, there are nonetheless many patients who do not tolerate or benefit from 
existing and the other third-line therapies including omalizumab [41].
MEDI-4212, ligelizumab (QGE031), and mAbs targeting the extracellular segment (M1′) of 
membrane IgE: quilizumab is a new anti-IgE reagents that is currently undergoing phase II 
trial testings [42, 43].
4.1. Ligelizumab (QGE031)
Ligelizumab is a completely humanized IgG1 monoclonal antibody directed in opposition to 
human IgE that binds with excessive affinity to the Cε3 area of IgE. It also binds to Cε3 area of 
IgE with much more affinity than omalizumab [41]. Compared to omalizumab, ligelizumab 
suggests sixfold to ninefold more suppression of allergen-induced skin prick exams in vivo. 
It also affords more and longer suppression of free IgE and IgE on the surface of circulating 
basophils compared to omalizumab [44].
Current findings suggest that ligelizumab can be more potent than omalizumab within the 
treatment of CSU. The advent of an even stronger anti-IgE mAb-ligelizumab is developing; 
in addition, possibilities for anti-IgE therapy to improve the symptoms and life quality of 
patients with chronic urticaria [40, 41].
4.2. Quilizumab
Quilizumab is a humanized monoclonal antibody that targets the M1 prime of membrane-
expressed IgE on IgE-switched B cells and plasmablasts. Quilizumab is in the medical devel-
opment for the remedy of allergic diseases. By inflicting the depletion of IgE-switched B cells 
and plasmablasts, it reduces serum IgE [45].
A currently achieved multicenter, double-blind observe with 32 CSU patients showed that 
there was no significant difference between quilizumab and placebo group in terms of 
decreases in disease scores [46]. But its longer period use in CSU patients or its combination 
with omalizumab may enhance treatment effects and lead to sustained responses. This has to 
be revealed in future studies [41].
These findings suggest that quilizumab may be an effective treatment of CSU. Quilizumab 
and ligelizumab are still under investigation in CSU [41].
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